About Amgen
Amgen is a biotechnology company based in Thousand Oaks, California, founded in 1980. Small beginnings mattered. It helped establish the biotechnology industry and uses biology, technology, and human genetic data in its research and development work.
The company develops and provides medicines for cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases, supported by a robust pipeline that builds on its existing portfolio of treatments. That work runs through discovery, development, and delivery, and it serves patients with a clear focus on those medicines.
Amgen employs more than 10,001 people and operates as one of the companies in the Dow Jones Industrial Average and the Nasdaq-100 Index. In 2024, it was named one of Fast Company’s “World’s Most Innovative Companies” and one of Forbes’ “America’s Best Large Employers.”
Need to reach the Amgen team directly? Find verified work emails for every employee with Snov.io
Insights
Updated 6 Jul 2026Amgen sits in a competitive group of large-cap healthcare names. A recent comparison article set it against Nuvalent across dividends, institutional ownership, profitability, valuation, analyst recommendations and earnings. Investors are still looking at more than the pipeline. They are weighing how durable Amgen’s financial profile looks beside emerging biotech peers.
Recent filing-based activity points to some caution. Raleigh Capital Management cut its Amgen stake by 36.6% in the first quarter, and after selling 2,316 shares it held 4,011 shares. That is a modest but clear negative sentiment signal from one holder, although it reflects only a single disclosed portfolio move.
No funding, hiring, or earnings updates were included in the supplied sources. So the main near-term signal is portfolio repositioning, not a fresh operating catalyst or company announcement.
Frequently asked questions
Amgen is headquartered in Thousand Oaks, California, United States.
Amgen has 10001+ employees according to its company profile.
Amgen operates in the Biotechnology sector. Public valuation figures are not always disclosed for private companies.